The Samuel Waxman Cancer Research Foundation (SWCRF) announced that Martin S. Tallman, MD, Chief of Leukemia Service at Memorial Sloan Kettering Cancer Center (MSK), has joined its Scientific Advisory Board. Dr. Tallman, who will continue in his role at MSK, will join his fellow Scientific Advisory Board members at the SWCRF Breakthroughs Scientific Review and Symposium in late April, which marks the annual evaluation of SWCRF-funded research programs.
The SWCRF Scientific Advisory Board, together with the Foundation’s scientific leaders, evaluates grant proposals submitted by scientists with National Cancer Institute (NCI)-approved research programs. The Foundation is a nonprofit organization dedicated to curing and preventing cancer. It is a pioneer in cancer research by funding research that identifies and corrects abnormal gene function that causes cancer. Since its inception in 1976, the Samuel Waxman Cancer Research Foundation has awarded approximately $100 million to support the work of more than 200 researchers across the globe. For more information, visit www.waxmancancer.org. ■